Literature DB >> 12188036

Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice.

Qianli Yu1, Dongqin Zhang, Michael Walston, Jin Zhang, Yingyin Liu, Ronald R Watson.   

Abstract

Methamphetamine (MA) abuse represents a growing problem in the USA with an increase of sudden death. To evaluate the immune function alterations due to chronic methamphetamine use, we examined C57BL/C mice with LP-BM5 retrovirus infection plus methamphetamine exposure. Mice were randomly assigned to the following groups: placebo, placebo retrovirus-infected, uninfected MA treated and retrovirus-infected MA treated. Placebo, MA-treated groups were intraperitoneally injected with saline, MA, respectively, with a gradually increasing dose from 15 to 40 mg/kg for 12 weeks (5 days/week). Con A- and LPS-induced mitogenesis of splenocytes, cytokine production by splenocytes culture and lipid peroxides in the liver were measured. Heart tissue histopathology was analyzed in all the groups with murine cytomegalovirus (CMV) superinfection. Our data showed that MA treatment significantly decreased production of IL-2 and interferon gamma (IFN-gamma) in uninfected mice but did not further suppress the reduced Th1 cytokines in retrovirus-infected mice. There were no significant effects on cytokines IL-4 and IL-6. However, tumor necrosis factor (TNF-alpha) was significantly increased in both uninfected and infected mice due to MA treatment. Lipid peroxides in liver were significantly increased both in uninfected and retrovirus-infected mice due to MA exposure. Vitamin E levels in liver were significantly decreased in uninfected mice due to MA treatment. CMV superinfection greatly increased the cardiac lesions in retrovirus-infected mice while no significant histopathology changes were detected due to MA treatment. Our data suggest that MA has immunomodulation activity, suppressing Th1 cytokine production and enhancing some Th2 cytokine secretion, as well as increasing lipid peroxides in uninfected mice. The interaction between LP-BM5 and MA remains unclear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12188036     DOI: 10.1016/s1567-5769(02)00047-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  37 in total

Review 1.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

3.  Adding fuel to the fire: methamphetamine enhances HIV infection.

Authors:  Raghava Potula; Yuri Persidsky
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

Review 4.  Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission.

Authors:  Xu Wang; Wen-Zhe Ho
Journal:  Life Sci       Date:  2010-11-04       Impact factor: 5.037

Review 5.  The Complex Interaction Between Methamphetamine Abuse and HIV-1 Pathogenesis.

Authors:  Ryan Colby Passaro; Jui Pandhare; Han-Zhu Qian; Chandravanu Dash
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-08       Impact factor: 4.147

6.  Methamphetamine enhances HIV infection of macrophages.

Authors:  Hao Liang; Xu Wang; Hui Chen; Li Song; Li Ye; Shi-Hong Wang; Yan-Jian Wang; Lin Zhou; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

7.  Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.

Authors:  Erinn S Raborn; Guy A Cabral
Journal:  J Pharmacol Exp Ther       Date:  2010-01-20       Impact factor: 4.030

8.  L-Deprenyl reverses age-associated decline in splenic norepinephrine, interleukin-2 and interferon-γ production in old female F344 rats.

Authors:  Srinivasan Thyagarajan; Kelley S Madden; Gary W Boehm; Suzanne Y Stevens; David L Felten; Denise L Bellinger
Journal:  Neuroimmunomodulation       Date:  2012-11-29       Impact factor: 2.492

Review 9.  Neuroimmune basis of methamphetamine toxicity.

Authors:  Jennifer M Loftis; Aaron Janowsky
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 10.  Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system.

Authors:  Thomas J Connor
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.